Pulse Biosciences (NSDQ:PLSE) said today that it launched a clinical feasibility study of its Nano-Pulse Stimulation platform intended to treat cutaneous warts.
The Nano-Pulse Stimulation system is a novel, non-thermal tech platform designed to deliver nanosecond duration energy pulses intended to disrupt functions of internal cell structures while maintaining outer cell membranes, the Hayward, Calif.-based company said.
Pulse Biosciences said that the device’s mechanism of action has been shown in previous clinical studies to eliminate treated cells with only mild inflammatory response and favorable healing and cosmetic outcomes.
“Although common warts are a widespread skin condition that every dermatologist sees regularly, we do not have reliable solutions to offer our patients. The unique non-thermal mechanism of NPS has been shown to affect deeper cellular structures without damaging the adjacent dermis. Our hope is that NPS treatment can reach and eliminate these deeper warts with better efficacy and without as much collateral tissue damage as thermal methods like laser heating or cryogen freezing of the tissue,” study principal investigator Dr. E. Ross of San Diego’s Scripps Clinic said in a prepared release.
In the study, investigators aim to enroll 20 subjects who will receive treatment followed by evaluations at 7, 30 and 60 days post-treatment. The company hopes to complete treatment and follow ups during the first quarter of next year.
“We’re pleased with the clinical progress we’re making in dermatology as we drive towards commercialization in this exciting market. We continue to demonstrate safety and efficacy in compelling dermatologic indications that also provide proof of the NPS mechanism in support of future indications in both benign and non-benign conditions,” prez & CEO Darrin Uecker said in a press release.
In August, Pulse Biosciences said it launched a clinical study evaluating NPS as a treatment for basal cell carcinoma.
